Benralizumab: A unique IL-5 inhibitor for severe asthma

Laren D. Tan, Jennifer M. Bratt, Dorottya Godor, Samuel Louie, Nicholas Kenyon

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations


The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalJournal of Asthma and Allergy
StatePublished - Apr 4 2016


  • Asthma
  • Asthma treatments
  • Benralizumab
  • Eosinophils
  • IL-5
  • IL-5Rα
  • MEDI-563

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Benralizumab: A unique IL-5 inhibitor for severe asthma'. Together they form a unique fingerprint.

Cite this